Business
Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical stage gene therapy company
About this update from Genprex, Inc.
[{"type":"text","content":" AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGenprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $3.50 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. There are no warrants in the offering. The gross proceeds of the offering will be approximately $17,500,000 before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds to advance its lead clinical programs in non-small cell lung cancer (NSCLC) and for working capital and general corporate purposes. The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.\n\n\nA.G.P./Alliance Global Partners is acting as lead placement agent for the offering.\n\n\nJoseph Gunnar & Co., LLC is acting as co-placement agent for the offering.\n\n\nThis offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-233774) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) under the Securities Act 1933, as amended, filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by Genprex with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, New York 10022 or by email at [email protected]. Joseph Gun...